alexa Gram-negative Bacterial Phagelysates In Anticancer Therapy
ISSN: 2161-0703

Journal of Medical Microbiology & Diagnosis
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

June 21-23, 2017 London, UK

K Gambashidze, A Sepashvili, P Khorava, T Azaladze, E Jaiani, B Lasareishvili and M Tediashvili
Tbilisi State Medical University, Georgia
Eliava Institute, Georgia
Posters & Accepted Abstracts: J Med Microb Diagn
DOI: 10.4172/2161-0703-C1-006
Application of bacterial preparations for anticancer immunomodulation is one of the promising ways of immunotherapy. Our experimental studies have shown high immunogenicity and less toxicity of E. coli and P. aeruginosa phagelysates than bacterial thermolysates. We were aimed to investigate antitumor immunomodulatory and adjuvant potential of Gram-negative bacterial phagelysates in cancer-bearing mice. Phage lysate of E. coli-Shigella specific Un bacteriophage was obtained by propagation of EcUnphage in semisynthetic medium and tested for: Sterility, viable bacterial cell content (CFU/ml), phage particles (PFU/ml), optical density (600 nm), protein concentration (Bradford method), endotoxins (LAL tests) and safety. Treatment effects (E. coli-Un phage lysate vaccinations 0.25 ml/day; Cyclophosphan 800 mg/m2) in Ehrlich carcinoma-bearing C57BL/6J mice were estimated by: index of malignant growth (using semi-empirical mathematical model V=Vo{exp[(t-to)/T]-1}; cancer growth inhibition percent; CD3CD4, CD3CD8, CD25Foxp3, NK-cells, IL-12, IFN-γ, TGF-β (using FACS-Array Bioanalyzer, BD-FACSCalibur, USA, WST-8 Cell-Proliferation Assay-Kit; ELISA according to manufactures protocol, R&D-systems). It was observed that E. coli-Un phage lysate vaccinations are well tolerated in mice. Chemotherapy inhibited cancer growth, but no increase in lifespan was observed. Phagelysates significantly increased efficacy of chemotherapy. Cancer development was inhibited by 80–90%. In 13%-19% of mice with 250-450 mm3 cancers complete regression of tumors was detected. Increase in Tc-effectors and cytokines and decrease in T-regs indicate E. coli-Un phage lysate anticancer immunomodulatory and adjuvant potential. It can be concluded that bacterial phage lysates can be used as powerful adjuvant in anticancer therapy.

K Gambashidze has completed her PhD from Tbilisi State Medical University, Georgia. She is an Associate Professor and Head of the Scientific Unit of Pathophysiology department of TSMU, Chairman of TSMU Animal Welfare and Use Ethics Committee. She has published more than 90 papers in reputed journals and has been serving as an Editorial Board Member of SOP journals: Open Journal of Biochemistry; Advances in Life Sciences and Health; Editor-in-Chief of SOP "Georgian Biomedical Journal", member of European Society for Medical Oncology (ESMO), CRI Cancer Immunotherapy Consortium (CRI/CIC), Association of Oncologists of Georgia, Georgian Association of Allergology and Clinical Immunology.

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version